Business

The Top 5 Biosimilars Articles for the Week of October 28

November 1st 2019

The Center for Biosimilars® recaps the top stories for the week of October 28, 2019.

FDA Says a "Broken Marketplace" to Blame for Drug Shortages

October 30th 2019

By Allison Inserro

Given how markets operate, pharmaceutical companies need financial incentives in order to keep providing a reliable stream of high-quality products that otherwise, due to low prices and other factors, might fall into shortage, according to an FDA report about the drug shortages problem released this week.

Q3 Numbers Show Biosimilar Momentum for Sandoz, Biogen, Pfizer, and Amgen

October 30th 2019

By Kelly Davio

Biosimilars are beginning to gain momentum, even in the sluggish US market, evidenced by strong US and global sales reported this month by some of the top biosimilar players.

Could Results for Revance's Novel Botulinum Toxin Make a Biosimilar Botox Less Appealing?

October 29th 2019

By Kelly Davio

Drug maker Revance Therapeutics has announced positive results from its SAKURA clinical program for its daxibotulinumtoxinA, a novel botulinum toxin type A that it hopes will compete with brand-name Botox, or onabotulinumtoxinA.

Formycon Starts Phase 1 Trial for Proposed Ustekinumab Biosimilar

October 28th 2019

By The Center for Biosimilars Staff

Drug maker Formycon announced today that it has begun a phase 1 clinical trial of its proposed ustekinumab biosimilar, FYB202, referencing Stelara. Ustekinumab is the first available therapy to target the interleukin-12 and -23 pathway.

Innovator Drug Developers Gain New Indications in Bids to Mitigate Biosimilar Impact

October 26th 2019

By The Center for Biosimilars Staff

As biosimilars for innovator biologics advance, drug makers are seeking new indications for products in their portfolios as a means to protect their sales against oncoming—or existing—competition. This month saw 3 notable label developments for drugs made by Janssen, Alexion, and AbbVie.

In Survey, Physicians Rank Their Own Confidence as the Primary Barrier to Biosimilar Adoption

October 25th 2019

By Kelly Davio

When it comes to considering using biosimilars, savings for patients are providers’ top concern, followed by savings to the healthcare system at large. Yet physicians also rate their own confidence levels in biosimilars as a main hurdle for widespread biosimilar adoption.

The Top 5 Biosimilars Articles for the Week of October 21

October 25th 2019

The Center for Biosimilars® recaps the top stories for the week of October 21, 2019.

Is a Window of Opportunity Closing for US Biosimilars?

October 24th 2019

By Kelly Davio

Writing in a viewpoint in JAMA, Walid F. Gellad, MD, MPH, and Chester B. Good, MD, MPH, both of the University of Pittsburgh, argue that the deep cost savings achieved in Europe for biosimilar adalimumab are unavailable to the United States because of settlements struck between AbbVie and the developers of all FDA-approved biosimilars.

WHO and IGBA Sign Agreement to Promote Biosimilars and Generics

October 23rd 2019

By The Center for Biosimilars Staff

The World Health Organization (WHO) and the International Generic and Biosimilar Medicines Association (IGBA), an umbrella organization with members including the Association for Accessible Medicines, Medicines for Europe, and a number of other national and regional generic and biosimilar organizations, have signed a memorandum of understanding.